

Impact of COVID-19 Pandemic on Cancer Screening in India: Current Situation, Challenges and Way Forwards

MD. Abu Bashar¹, Nazia Begam²

¹Department of Community Medicine, Institute of Medical Sciences, BHU, Varanasi, U.P, India. ²ECHS Hospital, Naraingarh, Ambala, Haryana, India.

Abstract

Cancer screening is a highly effective preventive measure that can reduce cancer incidence and mortality. COVID-19 pandemic has severely disrupted the ongoing screening activities for early diagnosis of cancers across the globe and the worst affected are low and middle income countries and India is no exception to it. This disruption to cancer screening services may have a significant impact on patients, health care practitioners, and health systems. Through this paper, we aim to offer a comprehensive view on the impact of COVID-19 on cancer screening in India and offer potential solutions to the problems arising out of the COVID-19 pandemic in cancer screening and prevention.

Keywords: Cancer- screening- COVID-19- telemedicine- education- training- social media

Asian Pac J Cancer Care, 6 (Suppl 1), 145-150

Submission Date: 08/16/2021 Acceptance Date: 10/14/2021

Introduction

As of August 13, 2021, as per World Health Organization (WHO), the COVID-19 pandemic has affected 222 countries and territories, with more than 205 million confirmed cases and more than 4.3 million deaths due to the disease [1]. The ongoing COVID-19 pandemic has resulted in widespread mortality and has exposed the frailties of health-care systems worldwide. National responses have varied from country to country, with restrictions or lockdowns of varying severity implemented to curb the pandemic, with different outcomes. There are concerns that several areas of health care, such as infant and maternal health, immunization, and non-communicable diseases could have been adversely affected by the pandemic [2, 3]. The reasons for these adverse consequences are multifactorial: health systems have been overwhelmed due to the prioritization of COVID-19 treatment over other diseases and the fear of COVID-19 transmission both among the general public and among the health-care providers has prevented care seeking. These effects are likely to be further compounded by the logistical challenges imposed on patients due to national and regional lockdowns and the economic slowdown and potential loss of wages.

On Jan 30th, 2020, the first case of COVID-19 was reported from India, and as of Aug 14th, 2021, around 32 million people have been infected with 430,254 individuals dying from the disease.¹ In response to the pandemic, the Government of India instituted a series of nationwide lockdowns that began on March 24th, 2020, with severe restrictions imposed on inter-state and intra-state travel. Some cancer centers were partially or completely converted to COVID-19 treatment facilities. Data from cancer centers across the world have shown that the provision of oncology services has been considerably reduced during the COVID pandemic [4-6]. Projections from many countries indicate increases in mortality in the next 5–10 years due to delays in diagnosis for several different cancer types [7-9]. In India, around 1.32 million patients are diagnosed with cancer annually [10] and cancer accounts for 8% of all deaths in the country [11]. Considerable disparities exist in cancer care in urban and rural areas [12-14]. Travel restrictions particularly during the first wave of the pandemic in India were likely to have affected access to care, especially for individuals in rural areas who are dependent on urban centres for cancer care. The coronavirus pandemic and the subsequent lockdowns

Corresponding Author:

Dr. MD Abu Bashar

Department of Community Medicine, Institute of Medical Sciences, BHU, Varanasi, U.P, India.

Email: imback20006@yahoo.in

have impacted not only cancer care but also the research in the field. The uncertainty has introduced new risks for cancer patients, disrupting the delivery of cancer treatment and the continuity of research.

Impact of COVID-19 on Cancer Screening in India

The pandemic has led to a challenging and unprecedented situation for those who did not know that they are having cancer or at risk of it. While cancer prevention and screening is integral to personal and population health, the cancer prevention and care sector is experiencing adverse changes due to the COVID-19 pandemic [15, 16]. One of the most severely impacted cancer control and prevention services is cancer screening. Cancer screening utilizes medical tests to identify precancerous lesions before cancer is developed or to detect cancer before it progresses into more advanced stages [17, 18]. Screening is an effective preventive strategy that could substantially reduce cancer incidence and mortality rates in patients [19-22]. Evidence shows that for women of all ages at average risk, screening is linked to an approximate 20% reduction in breast cancer mortality [23]. Studies further indicate that 3 times the deaths resulting from colorectal cancer could be avoided with one third of current costs if colorectal cancer screening rates in people aged 50-70 years is improved to 80% [24]. For the genetically predisposed individual, the benefit of prescribed cancer screening has an even greater impact [25, 26].

COVID-19 has significantly hampered the cancer screening infrastructure [15]. To adjust the provision of health care resources, many cancer agencies have championed the idea of halting cancer screening services to patients [27-29]. In United states (US), it is estimated that as a result of COVID-19, screenings for cancers of the breast, colon, and cervix have dropped by 94%, 86%, and 94% between January 20, 2020, and April 21, 2020, respectively [30].

As per GLOBOCAN 2018, India alone contributed to 1,157,294 (13.2%) of the total cancer cases of the Asian continent (8,750,9321 cases) with more than one-third being oral, breast and cervical cancer cases [31]. India has the highest estimated lip and oral cavity cancer cases worldwide (119,992, 33.8%) and the second-highest number of the breast (162,468, 17.8%) and cervix uteri (96,922, 30.7%) cancers in Asian sub-continent [31]. Not only India has a high cancer burden, the majority (75-80%) of cancer patients have advanced disease (Stage 3-4) at the time of diagnosis owing to lack of screening services in most part of the country. Rural areas of India (where 69% of the total population resides) have an even worse situation, where cancer patients and families have to travel long distances to receive treatment and care at a tertiary care oncology center [32].

The government of India had launched an operational framework for the country's first national cancer screening program in 2016 under the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS). As per the guidelines, there will be both population and facility

based screening for oral, breast, and cervical cancer in people over the age of 30 in 100 districts of India before the program is expanded to other areas of the country [33, 34].

On 19th May 2020, due to the COVID-19 pandemic impact, the Government of India had suspended the population based screening of people above 30 years of age as part of the national program based on the risk associated with oral cavity examination. However, emergency cases requiring a biopsy will be addressed as per the protocol. These were temporary guidelines and subject to revision depending on change in the overall situation [35]. Thereby, the early detection of cancer services were primarily be restricted to out-patient settings in primary, secondary and tertiary care centers.

Even before COVID-19 pandemic, population-based screening was confined to only few geographical regions in India due to various reasons including infrastructure and manpower constraints. Majority of cancer patients in India are diagnosed only when they visit hospital out-patient settings with early signs and symptoms [36]. Therefore, it is necessary that early detection services should be kept functional at out-patient settings so that at least the patients coming to hospitals with early signs and symptoms can be diagnosed as early as possible.

Opportunities and Solutions

a) Use of Telemedicine for Cancer Screening & Prevention

With the advances in science and technology, the application of telemedicine in cancer care and management have gained momentum [37-39]. Telemedicine, literally means "healing at a distance" [40], could be understood as the delivery of health care services aiming to advance personal and population health [41]. Telemedicine allows timely, accessible, and cost-effective health care delivery to patients, which qualifies itself a practical solution to the COVID-19-induced constraints such as social distancing and self-isolation [42-44]. Telemedicine tools such as virtual reality devices have been found to be useful for training health care practitioners [45]. As virtual reality can offer remote yet realistic training experiences, it facilitates training for health care professionals in a time when social isolation is the norm. Telemedicine has been shown to be effective in underserved geographically remote populations. Emerging technologies such as artificial intelligence (AI) also have great potential in facilitating cancer screening [40]. On a higher-technological state, using a deep learning technique, researchers found that AI can help identify faces of patients with cancer from those without [46]. This promising finding, not currently in use, suggests that AI-based telemedicine tools have the future potential to assist patients and health care practitioners with cancer screening and improve screening accuracy.

While promising telemedicine opportunities are present, to successfully implement telemedicine in cancer care and primary care, education and training should be made available to both patients and health care practitioners [39]. Research conducted by Stanford University shows that 47% of physicians and 73% of medical students surveyed indicated that they are considering taking

additional courses to better prepare for innovations in health care (e.g.; data science, AI) [47]. While it is of vital importance to update college curricula to reflect health care needs identified in practice [48, 49], it is important to understand that telemedicine education and training should be considered as a long-term investment, rather than a short-term experiment. In other words, as technology advances, telemedicine education and training programs should also be updated regularly and frequently to ensure health care practitioners are up to date with telemedicine opportunities for the benefits of self and patients [50, 51].

b) Leveraging Social Media to Boost Cancer Screening

In addition to boosting health care professionals' core competence with respect to telemedicine, health systems should also consider adopting integrated marketing campaigns, such as social media campaigns, to increase screening awareness and adoption rates in patients. Social media campaigns could be understood as the use of social media platforms to deliver persuasive communication strategies to the target audience in order to change their attitudes and behavior to improve health. One key advantage of social media campaigns is that as persuasive strategies adopted in these campaigns are evidence-based and tailored to the target audience, [52, 53] they often yield desirable campaign outcomes [54-56].

Social media campaigns may be extremely useful for promoting cancer screening services to at-risk populations. Compared to integrated marketing campaigns distributed via traditional media platforms, social media campaigns can be distributed remotely with limited costs and therefore have the added advantages of cost-effectiveness and scalability [52, 53]. This advantage might be more pronounced in the era of COVID-19; since lockdowns and social distancing measures have limited people's ability to physically disseminate campaign messages, campaign mechanisms that can virtually distribute promotional information are desired. Evidence suggests that social media campaigns are effective in raising cancer screening awareness in the target audience [57-59]. Promising findings show that social media campaigns on lung cancer screening using Google and Facebook to reach at-risk populations yielded click-through rates above the industry standard [58]. These insights suggest that health care professionals can consider using social media campaigns to reach at-risk populations, such as marginalized communities with pronounced needs to be screened for cancer, to further address the widening cancer disparities exacerbated by COVID-19.

In conclusion, the systemic disruption and tragedy that COVID-19 has brought to patients, practitioners, and health care systems globally is a window of opportunity for innovative solutions' in the field of cancer screening and prevention. Cancer prevention professionals need to innovate in the current changed environment in order to continue reducing the burden of cancers and sufferings arising out of them in communities. We need agile short-term plans tailored to the current COVID-19 situation as well as long-term plans that account for the

capricious, costly, and deadly nature of cancer and its intersection with other widespread health problems, such as viral infections similar to the current pandemic. We offer some post-COVID-19 screening recommendations as follows:

- Breast cancer screening
- Educating the community through various channels on how to perform a "breast self-examination"
- Cervical cancer screening
- Visual inspection under acetic acid(VIA)+/- Pap smears at the health facilities following COVID guidelines
- Oral cancer screening
- To be conducted by the health worker only if PPE kits are available at the health facility. Education through various medias and channels on how to self-examine the oral cavity and identify any "abnormal lesion"
- General solutions:
 - Proactive outreach to patients due for screening or population at risk of cancer
 - Social media communication to patients about risks of cancer and safety of screening procedures
 - Initial assessment and results follow-up via telemedicine appointment
 - Masking precautions (patient, clinician, and staff)
 - Social distancing precautions wherever possible

Contentment is not a choice in the current situation, and health care professionals must diligently work together with other stakeholders and across disciplines to find solutions to ensure patients, providers, and health systems have the necessary tools and means to screen for cancer in the new changed scenario.

References

1. WHO Coronavirus (COVID-19) Dashboard. Available from: <https://covid19.who.int/> [Last accessed on August 14, 2021].
2. Watkins J, Wulaningsih W. Three further ways that the COVID-19 pandemic will affect health outcomes. *International Journal of Public Health*. 2020 06;65(5):519-520. <https://doi.org/10.1007/s00038-020-01383-6>
3. Rosenbaum L. The Untold Toll - The Pandemic's Effects on Patients without Covid-19. *The New England Journal of Medicine*. 2020 06 11;382(24):2368-2371. <https://doi.org/10.1056/NEJMms2009984>
4. Jereczek-Fossa BA, Pepa M, Marvaso G, Bruni A, Buglione di Monale E, Bastia M, Catalano G, Filippi AR, Franco P, Gambacorta MA, Genovesi D, Iati G, Magli A, Marafioti L, Meattini I, Merlotti A, Mignogna M, Musio D, Pacelli R, Pergolizzi S, Tombolini V, Trovò M, Ricardi U, Magrini SM, Corvò R, Donato V. COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). *Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology*. 2020 08;149:89-93. <https://doi.org/10.1016/j.radonc.2020.04.061>
5. Vasquez L, Sampor C, Villanueva G, Maradiegue E, Garcia-Lombardi M, Gomez-García W, Moreno F, Diaz R, Cappellano AM, Portilla CA, Salas B, Nava E, Brizuela S, Jimenez S, Espinoza X, Gassant PY, Quintero K, Fuentes-Alabi S, Velasquez T, Fu L, Gamboa Y, Quintana J, Castiglioni M, Nuñez C, Moreno A, Luna-Fineman S, Luciani S, Chantada G. Early impact of the COVID-19

- pandemic on paediatric cancer care in Latin America. *The Lancet. Oncology*. 2020 06;21(6):753-755. [https://doi.org/10.1016/S1470-2045\(20\)30280-1](https://doi.org/10.1016/S1470-2045(20)30280-1)
6. Martinez D, Sarria GJ, Wakefield D, Flores C, Malhotra S, Li B, Ehmann M, Schwartz DL, Sarria GR. COVID's Impact on Radiation Oncology: A Latin American Survey Study. *International Journal of Radiation Oncology, Biology, Physics*. 2020 Oct 01;108(2):374-378. <https://doi.org/10.1016/j.ijrobp.2020.06.058>
 7. Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, Rachet B, Aggarwal A. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. *The Lancet. Oncology*. 2020 08;21(8):1023-1034. [https://doi.org/10.1016/S1470-2045\(20\)30388-0](https://doi.org/10.1016/S1470-2045(20)30388-0)
 8. Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, Garrett A, Gronthoud F, Nicol DL, Jhanji S, Boyce SA, Williams M, Riboli E, Muller DC, Kipps E, Larkin J, Navani N, Swanton C, Lyratzopoulos G, McFerran E, Lawler M, Houlston R, Turnbull C. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. *The Lancet. Oncology*. 2020 08;21(8):1035-1044. [https://doi.org/10.1016/S1470-2045\(20\)30392-2](https://doi.org/10.1016/S1470-2045(20)30392-2)
 9. Sharpless NE. COVID-19 and cancer. *Science (New York, N.Y.)*. 2020 06 19;368(6497):1290. <https://doi.org/10.1126/science.abd3377>
 10. WHO International Agency for Research on Cancer. GLOBOCAN 2020. India. Available from: <https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf> [Last accessed August 14, 2021].
 11. Dhillion PK, Mathur P, Nandakumar A, et al .The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990-2016. *The Lancet. Oncology*. 2018 Oct;19(10):1289-1306. [https://doi.org/10.1016/S1470-2045\(18\)30447-9](https://doi.org/10.1016/S1470-2045(18)30447-9)
 12. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PER, Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao Y, Shao Z, Wu Y, Fan D, Chow LWC, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD, Nair R, Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S, Kaidarova D, Tsimafeyev I, Tatishchev S, Danishevskiy KD, Hurlbert M, Vail C, St Louis J, Chan A. Challenges to effective cancer control in China, India, and Russia. *The Lancet. Oncology*. 2014 04;15(5):489-538. [https://doi.org/10.1016/S1470-2045\(14\)70029-4](https://doi.org/10.1016/S1470-2045(14)70029-4)
 13. Mallath MK, Taylor DG, Badwe RA, Rath GK, Shanta V, Pramesh CS, Digumarti R, Sebastian P, Borthakur BB, Kalwar A, Kapoor S, Kumar S, Gill JL, Kuriakose MA, Malhotra H, Sharma SC, Shukla S, Viswanath L, Chacko RT, Pautu JL, Reddy KS, Sharma KS, Purushotham AD, Sullivan R. The growing burden of cancer in India: epidemiology and social context. *The Lancet. Oncology*. 2014 05;15(6):e205-212. [https://doi.org/10.1016/S1470-2045\(14\)70115-9](https://doi.org/10.1016/S1470-2045(14)70115-9)
 14. Pramesh CS, Badwe RA, Borthakur BB, Chandra M, Raj EH, Kannan T, Kalwar A, Kapoor S, Malhotra H, Nayak S, Rath GK, Sagar TG, Sebastian P, Sarin R, Shanta V, Sharma SC, Shukla S, Vijayakumar M, Vijaykumar DK, Aggarwal A, Purushotham A, Sullivan R. Delivery of affordable and equitable cancer care in India. *The Lancet. Oncology*. 2014 05;15(6):e223-233. [https://doi.org/10.1016/S1470-2045\(14\)70117-2](https://doi.org/10.1016/S1470-2045(14)70117-2)
 15. Waterhouse DM, Harvey RD, Hurley P, Levit LA, Kim ES, Klepin HD, Mileham KF, Nowakowski G, Schenkel C, Davis C, Bruinooge SS, Schilsky RL. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. *JCO oncology practice*. 2020 07;16(7):417-421. <https://doi.org/10.1200/OP.20.00275>
 16. Ren X, Chen B, Hong Y, Liu W, Jiang Q, Yang J, Qian Q, Jiang C. The challenges in colorectal cancer management during COVID-19 epidemic. *Annals of Translational Medicine*. 2020 04;8(7):498. <https://doi.org/10.21037/atm.2020.03.158>
 17. Cancer: Screening. World Health Organization. Available from: <https://www.who.int/cancer/prevention/diagnosis-screening/screening/en/> [Last accessed on August 14, 2021].
 18. Division of Cancer Prevention and Control Screening tests. Centers for Disease Control and Prevention. 2020. Available from: <https://www.cdc.gov/cancer/dccp/prevention/screening.htm>. [Last accessed on August 14, 2021].
 19. Lieberman D, Sullivan BA, Hauser ER, Qin X, Musselwhite LW, O'Leary MC, Redding TS, Madison AN, Bullard AJ, Thomas R, Sims KJ, Williams CD, Hyslop T, Weiss D, Gupta S, Gellad ZF, Robertson DJ, Provenzale D. Baseline Colonoscopy Findings Associated With 10-Year Outcomes in a Screening Cohort Undergoing Colonoscopy Surveillance. *Gastroenterology*. 2020 03;158(4):862-874.e8. <https://doi.org/10.1053/j.gastro.2019.07.052>
 20. Ran T, Cheng C, Misselwitz B, Brenner H, Ubels J, Schlander M. Cost-Effectiveness of Colorectal Cancer Screening Strategies-A Systematic Review. *Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association*. 2019 09;17(10):1969-1981.e15. <https://doi.org/10.1016/j.cgh.2019.01.014>
 21. Miller EA, Pinsky PF, Schoen RE, Prorok PC, Church TR. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial. *The Lancet. Gastroenterology & Hepatology*. 2019 02;4(2):101-110. [https://doi.org/10.1016/S2468-1253\(18\)30358-3](https://doi.org/10.1016/S2468-1253(18)30358-3)
 22. Hollowell BD, Endeshaw M, McKenna MT, Senkomago V, Razzaghi H, Saraiya M. Cervical Cancer Death Rates Among U.S.- and Foreign-Born Women: U.S., 2005-2014. *American Journal of Preventive Medicine*. 2019 06;56(6):869-874. <https://doi.org/10.1016/j.amepre.2019.01.007>
 23. Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, Davidson B, Montgomery RC, Crowley MJ, McCrory DC, Kendrick A, Sanders GD. Benefits and Harms of Breast Cancer Screening: A Systematic Review. *JAMA*. 2015 Oct 20;314(15):1615-1634. <https://doi.org/10.1001/jama.2015.13183>
 24. Ladabaum U, Mannalithara A, Meester RGS, Gupta S, Schoen RE. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years. *Gastroenterology*. 2019 07;157(1):137-148. <https://doi.org/10.1053/j.gastro.2019.03.023>
 25. Gupta S, Provenzale D, Regenbogen SE, Hampel H, Slavin TP, Hall MJ, Llor X, Chung DC, Ahnen DJ, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Halverson AL, Hamilton SR, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Markowitz AJ, Mayer RJ, Ness RM, Samadder NJ, Shike M, Sugandha S, Weiss JM, Dwyer MA, Ogba N. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. *Journal of*

- the National Comprehensive Cancer Network: JNCCN. 2017 Dec;15(12):1465-1475. <https://doi.org/10.6004/jnccn.2017.0176>
26. Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. *Journal of the National Comprehensive Cancer Network: JNCCN*. 2020 04;18(4):380-391. <https://doi.org/10.6004/jnccn.2020.0017>
 27. ASBrS and ACR joint statement on breast screening exams during the COVID-19 pandemic. *The American Society of Breast Surgeons*. 2020. Mar 26, [2020-09-01]. <https://www.breastsurgeons.org/news/?id=45>.
 28. Falco M. Common questions about the new coronavirus outbreak. *American Cancer Society*. 2020. Oct 12, [2020-10-19]. <https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html>.
 29. ASCCP interim guidance for timing of diagnostic and treatment procedures for patients with abnormal cervical screening test. *American Society for Colposcopy and Cervical Pathology*. 2020. Mar 19, [2020-09-01]. <https://www.asccp.org/covid-19>.
 30. Preventive cancer screenings during COVID-19 pandemic. *Epic Health Research Network*. 2020. Available from: <https://ehrn.org/delays-in-preventive-cancer-screenings-during-covid-19-pandemic/> [Last accessed on August 14, 2021].
 31. International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2018—estimated cancer incidence, mortality and prevalence worldwide in 2018. 2018. Available from: <https://gco.iarc.fr/> [Last accessed on August 14, 2021].
 32. Singh M, Prasad CP, Singh TD, Kumar L. Cancer research in India: Challenges & opportunities. *The Indian Journal of Medical Research*. 2018 Oct;148(4):362-365. https://doi.org/10.4103/ijmr.IJMR_1711_18
 33. Bagochi S. India launches plan for national cancer screening programme. *BMJ (Clinical research ed.)*. 2016 Oct 17;355:i5574. <https://doi.org/10.1136/bmj.i5574>
 34. Director General of Health Services. Ministry of Health and Family Welfare. Government of India. National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS). Published 2016. Available from: https://dghs.gov.in/content/1363_3_NationalProgrammePreventionControl.aspx [Last accessed on August 14, 2021].
 35. Sharma DC. Lockdown poses new challenges for cancer care in India. *The Lancet. Oncology*. 2020 07;21(7):884. [https://doi.org/10.1016/S1470-2045\(20\)30312-0](https://doi.org/10.1016/S1470-2045(20)30312-0)
 36. Sivaram S, Majumdar G, Perin D, Nessa A, Broeders M, Lyng E, Saraiya M, Segnan N, Sankaranarayanan R, Rajaraman P, Trimble E, Taplin S, Rath GK, Mehrotra R. Population-based cancer screening programmes in low-income and middle-income countries: regional consultation of the International Cancer Screening Network in India. *The Lancet. Oncology*. 2018 02;19(2):e113-e122. [https://doi.org/10.1016/S1470-2045\(18\)30003-2](https://doi.org/10.1016/S1470-2045(18)30003-2)
 37. Sirintrapun SJ, Lopez AM. Telemedicine in Cancer Care. *American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting*. 2018 05 23;38:540-545. https://doi.org/10.1200/EDBK_200141
 38. Fertleman C, Aubugeau-Williams P, Sher C, Lim A, Lumley S, Delacroix S, Pan X. A Discussion of Virtual Reality As a New Tool for Training Healthcare Professionals. *Frontiers in Public Health*. 2018;6:44. <https://doi.org/10.3389/fpubh.2018.00044>
 39. Mette LA, Saldívar AMP, Poullard NE, Torres IC, Seth SG, Pollock BH, Tomlinson GE. Reaching high-risk underserved individuals for cancer genetic counseling by video-teleconferencing. *The Journal of Community and Supportive Oncology*. 2016 04;14(4):162-168. <https://doi.org/10.12788/jcso.0247>
 40. Strehle EM, Shabde N. One hundred years of telemedicine: does this new technology have a place in paediatrics?. *Archives of Disease in Childhood*. 2006 Dec;91(12):956-959. <https://doi.org/10.1136/adc.2006.099622>
 41. Telemedicine: Opportunities and developments in member states. *World Health Organization*. 2010. Available from: https://www.who.int/goe/publications/goe_telemedicine_2010.pdf. [Last accessed on August 14, 2021].
 42. Lewis GD, Hatch SS, Wiederhold LR, Swanson TA. Long-Term Institutional Experience With Telemedicine Services for Radiation Oncology: A Potential Model for Long-Term Utilization. *Advances in Radiation Oncology*. 2020 05 08;5(4):780-782. <https://doi.org/10.1016/j.adro.2020.04.018>
 43. Ochs M, Mestre D, Montcheuil G, Pergandi J, Saubesty J, Lombardo E, FRANCON D, Blache P. Training doctors' social skills to break bad news: evaluation of the impact of virtual environment displays on the sense of presence. *Journal on Multimodal User Interfaces*. 2019 03;13(1):41-51. <https://doi.org/10.1007/s12193-018-0289-8>
 44. Lopez AM. Telemedicine, telehealth, and e-health technologies in cancer prevention. *Fundamentals of Cancer Prevention, Third Edition*. 2014 01 01;:259-277. https://doi.org/10.1007/978-3-642-38983-2_9
 45. Mendu S, Boukhechba M, Gordon JR, Datta D, Molina E, Arroyo G, Proctor SK, Wells KJ, Barnes LE. Design of a Culturally-Informed Virtual Human for Educating Hispanic Women about Cervical Cancer. *International Conference on Pervasive Computing Technologies for Healthcare : [proceedings]. International Conference on Pervasive Computing Technologies for Healthcare*. 2018 05;2018:360-366. <https://doi.org/10.1145/3240925.3240968>
 46. Liang B, Yang N, He G, Huang P, Yang Y. Identification of the Facial Features of Patients With Cancer: A Deep Learning-Based Pilot Study. *Journal of Medical Internet Research*. 2020 04 29;22(4):e17234. <https://doi.org/10.2196/17234>
 47. The rise of the data-driven physician. *Stanford University*. Available from: https://med.stanford.edu/content/dam/sm/school/documents/Health-Trends_Report/Stanford%20Medicine%20Health%20Trends%20Report%202020.pdf. [Last accessed on August 14, 2021].
 48. Lee A, Moy L, Kruck S, Rabang J. The doctor is in, but is academia? Re-tooling IT education for a new era in healthcare. *Journal of Information Systems Education*. 2014;25(4):275-82.
 49. Carroll N, Richardson I, Maloney M, O'Reilly P. Bridging healthcare education and technology solution development through experiential innovation. *Health and Technology*. 2017;. <https://doi.org/10.1007/s12553-017-0209-z>
 50. Botrugno C. Information technologies in healthcare: Enhancing or dehumanising doctor-patient interaction?. *Health (London, England)*. 2021 07;25(4):475-493. <https://doi.org/10.1177/1363459319891213>
 51. Bidgoli H. Successful Integration of Information Technology in Healthcare: Guides for Managers. *Journal of Strategic*

- Innovation and Sustainability. 2018 09 01;13(3). <https://doi.org/10.33423/jsis.v13i3.615>
52. Noar S, Harrington N, Aldrich R. The Role of Message Tailoring in the Development of Persuasive Health Communication Messages. *Annals of the International Communication Association*. 2016;33(1):73-133.
53. Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health behaviour. *Lancet (London, England)*. 2010 Oct 09;376(9748):1261-1271. [https://doi.org/10.1016/S0140-6736\(10\)60809-4](https://doi.org/10.1016/S0140-6736(10)60809-4)
54. Key T, Czapslewski A. Upstream social marketing strategy: An integrated marketing communications approach. *Business Horizons*. 2017;60(3):325-33.
55. Patti C, Hartley S, van Dessel M, et al. Improving integrated marketing communications practices: A comparison of objectives and results. *Journal of Marketing Communications*. 2015;23(4):351-70.
56. Merrill RM, Telford CT. Pharmaceutical use according to participation in worksite wellness screening and health campaigns. *Preventive Medicine Reports*. 2018 Dec;12:158-163. <https://doi.org/10.1016/j.pmedr.2018.09.008>
57. Jessup D, Glover Iv McKinley, Daye D, Banzi L, Jones P, Choy G, Shepard J, Flores E. Implementation of Digital Awareness Strategies to Engage Patients and Providers in a Lung Cancer Screening Program: Retrospective Study. *J Med Internet Res*. 2018;20(2):e52.
58. Harty NM, Le Grice K, Cahill C, Bull S, Dwyer A. EndCancer: development and pilot testing of multimedia recruitment for a text message campaign to increase cancer screening. *mHealth*. 2018 Oct 31;4:50. <https://doi.org/10.21037/mhealth.2018.10.02>
59. Springer SM, McFall A, Hager P, Percy-Laury A, Vinson CA. Lung cancer screening: an emerging cancer control issue presents opportunities for an awareness campaign in rural Michigan. *Cancer causes & control: CCC*. 2018 Dec;29(12):1257-1263. <https://doi.org/10.1007/s10552-018-1080-6>



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.